U.S. markets close in 3 hours 45 minutes
  • S&P 500

    3,856.34
    +27.00 (+0.71%)
     
  • Dow 30

    31,279.95
    -122.06 (-0.39%)
     
  • Nasdaq

    13,353.46
    +234.03 (+1.78%)
     
  • Russell 2000

    2,211.60
    +11.43 (+0.52%)
     
  • Crude Oil

    62.32
    -1.21 (-1.90%)
     
  • Gold

    1,718.10
    -57.30 (-3.23%)
     
  • Silver

    26.23
    -1.45 (-5.26%)
     
  • EUR/USD

    1.2092
    -0.0094 (-0.77%)
     
  • 10-Yr Bond

    1.5010
    -0.0170 (-1.12%)
     
  • GBP/USD

    1.3943
    -0.0070 (-0.50%)
     
  • USD/JPY

    106.6680
    +0.4380 (+0.41%)
     
  • BTC-USD

    48,175.48
    -2,718.18 (-5.34%)
     
  • CMC Crypto 200

    966.72
    +33.58 (+3.60%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Here's Why You Should Avoid Betting on Barnes Group (B) Now

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Barnes Group Inc. B has failed to impress investors with its recent operational performance, owing to difficult end-market conditions amid the coronavirus outbreak and other challenges, which are expected to adversely impact its earnings.

The Zacks Rank #5 (Strong Sell) company has a market capitalization of nearly $2 billion. In the past six months, it has lost 41.8% compared with the industry’s decline of 7.8%.

 


 

Let’s delve into the factors that might continue to take a toll on the firm.

Weak End-Markets: In the quarters ahead, continued softness in automotive and industrial end markets on account of low order intakes will likely continue to adversely impact Barnes Group’s Industrial segment. Also, reduced aircraft utilization and lower aircraft demand remain concerning for the Aerospace segment’s aftermarket and OEM businesses. Notably, the company’s organic sales are predicted to decline 30% in third-quarter 2020 on a year-over-year basis. Owing to the uncertainties regarding the impacts of the pandemic on its operating results, it refrained from providing financial guidance for 2020.

High Costs & Expenses: The company has been dealing with rising costs and expenses over time. For instance, in the last five years (2015-2019), its cost of sales recorded an increase of 3.8% (CAGR). Also, the company’s selling, general and administrative expenses grew 5% (CAGR) during the same time frame. Notably, exiting second-quarter 2020, its cost of sales, and selling, general and administrative expenses were recorded at $147.1 million and $78.4 million, respectively.

Forex Woes: Given its widespread presence in international markets, Barnes Group is exposed to the unfavorable foreign currency movements. For instance, in the first and second quarters of 2020, foreign exchange headwinds hurt its top-line performance by 1%.

Estimate Trend: In the past 30 days, analysts have increasingly become bearish on the company, as evident from negative earnings estimate revisions. Notably, the Zacks Consensus Estimate for its 2020 earnings has trended down from $1.82 to $1.73 on two downward estimate revisions against one upward. In addition, over the same timeframe, the consensus estimate for 2021 earnings has trended down from $2.25 to $2.01 on three downward estimate revisions against none upward.

Stocks to Consider

Some better-ranked stocks from the same space are Chart Industries, Inc. GTLS, Altra Industrial Motion Corp. AIMC and Graco Inc. GGG. While Chart Industries sports a Zacks Rank #1 (Strong Buy), Altra Industrial and Graco carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Chart Industries delivered an earnings surprise of 10.17%, on average, in the trailing four quarters.

Altra Industrial delivered an earnings surprise of 31.43%, on average, in the trailing four quarters.

Graco delivered an earnings surprise of 8.68%, on average, in the trailing four quarters.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Graco Inc. (GGG) : Free Stock Analysis Report
 
Chart Industries, Inc. (GTLS) : Free Stock Analysis Report
 
Barnes Group, Inc. (B) : Free Stock Analysis Report
 
Altra Industrial Motion Corp. (AIMC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research